Lift Biosciences Limited

Lift Biosciences Limited, a small, active company from London, UK, was founded ten years ago and employs sixteen people. Operating from a virtual address, the company is led by four directors and has one owner, Fickel James Robert. It's a regular importer of plastics and plastic products, with fifteen months of import activity recorded.

The company's website highlights its focus on "innately curing cancer" through Immunomodulatory Alpha Neutrophils (IMANs). It positions itself as a world leader in neutrophil immunotherapy, emphasizing a unique dual mechanism of action that both directly kills cancer cells and recruits the immune system. Recent news includes presentations at the International Society for Cell and Gene Therapy, a partnership with the University of Galway, and appointments of key personnel like Dr. Mark A. Exley as Chief Scientific Officer. Lift Biosciences has offices in London, Galway (Ireland), and Boston (US), and caters to commercial and industrial customers.

Financially, Lift Biosciences shows a mixed picture. Cash reserves increased significantly by 140% to £3.6 million, a positive sign. However, net losses deepened to -£530,000, and total equity declined to £16 million. Bank borrowings surged, reaching £42,000, and trade debtors increased, suggesting potential payment delays. Despite these challenges, the company’s intangible assets grew by 41% to £11 million, reflecting investments in research and development. The company is exempt from an audit, and the unaudited financial statements were signed in February 2025.

Registered in England/Wales under the registration number 09277638, with a registered address at NW1 0NH, England, London, London Bioscience Innovation Centre, 2 Royal College Street.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.